Ucb SA UCB-BE:Euronext Brussels

*Data is delayed | EUR
Last | 5:35 PM CET
86.00quote price arrow up+4.68 (+5.76%)
Volume
788,874
52 week range
60.18 - 114.45

...

Loading . . .

KEY STATS

  • Open83.84
  • Day High88.34
  • Day Low83.84
  • Prev Close81.32
  • 52 Week High114.45
  • 52 Week High Date07/17/20
  • 52 Week Low60.18
  • 52 Week Low Date03/19/20
  • Market Cap19,238.72M
  • Shares Out189.12M
  • 10 Day Average Volume275,967.58
  • Dividend1.24
  • Dividend Yield1.44%
  • Beta0.37
  • 1 Year % Change-2.25

RATIOS/PROFITABILITY

  • EPS (TTM)3.87
  • P/E (TTM)22.22
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date05/04/2020
  • Div Amount1.24
  • Split Date-
  • Split Factor-

Latest Ucb SA News

There is no recent news for this security.

Latest UCB-BE News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and...
Evelyn Diego du Monceau de Bergendal
Non-Executive Chairman
Sandrine Dufour
Chief Financial Officer
Charl van Zyl
Executive Vice President
Emmanuel Caeymaex
Executive Vice President
Iris Loew-Friedrich
Executive Vice President
Antje Witte
Vice President
Address
Allee de la Recherche, 60
Anderlecht
1070
Belgium